Akero Therapeutics, Inc.

AIM-NASH, the first artificial intelligence (AI)-based pathology tool to be qualified by the European Medicines Agency for assessing drug candidates for metabolic dysfunction-associated steatohepatiti

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and